CPT code 23620: Greater humeral tuberosity fracture billing guide
CPT code 23620 describes the closed treatment of a greater humeral tuberosity fr...
Last Updated: August 19, 2026
Key takeaways
HCPCS code J1438 covers an injection of etanercept (Enbrel), 25 mg. It is only billable when a physician administers the drug under direct supervision.
Medicare Part B reimburses J1438 at ASP plus 6 percent. CMS updates the rates quarterly, so verify the current figure before billing.
One unit of J1438 equals 25 mg, so a standard 50 mg dose requires 2 units. Miscalculating units is the most common billing error for this code.
Practice management software like Pabau links the administration record to charge capture, so the visit note and the billed units agree.
HCPCS code J1438 is a billable J-code for an injection of etanercept, 25 mg, the biologic sold as Enbrel. Its official descriptor limits it to Medicare claims where a physician administers the drug under direct supervision. It cannot be billed when the patient self-administers at home.
Etanercept is the generic name and Enbrel is the Amgen brand. The drug is a tumor necrosis factor (TNF) inhibitor, a class of biologics that blocks the cytokine driving inflammation in autoimmune disease. J1438 has been active continuously and remains valid for 2026 per the CMS HCPCS code file.
Code details at a glance
Approved indications and matching ICD-10 codes
Etanercept carries FDA approval for five distinct indications, and each one maps to a specific ICD-10-CM category. Coders should select the most specific subcategory available within each range, based on the clinical documentation. The table below shows the primary category for each approved indication.
Off-label use of etanercept is not covered by Medicare under J1438 without specific coverage policy support. Claims submitted with a diagnosis outside the FDA-approved indications carry a high risk of denial. Document the indication explicitly in the visit note, which is simpler when your dermatology EMR software uses structured diagnosis fields.
Medicare coverage and supervision requirements
Medicare covers HCPCS code J1438 under Part B rather than through the Part D pharmacy benefit. That matters because a Part B drug is billed by the provider on a CMS-1500 claim. A Part D drug is dispensed through a pharmacy instead. Enbrel given in a physician office or infusion center qualifies for Part B coverage when all of the following conditions are met.
- The drug is administered under the direct supervision of a physician. Direct supervision means the physician is present in the office suite and immediately available, though not necessarily in the room.
- The patient does not self-administer the drug. If a patient injects at home, billing J1438 on a Part B claim is incorrect regardless of where the prescription originated.
- The claim is submitted with a valid ICD-10 diagnosis that supports an FDA-approved indication for etanercept.
- An appropriate place-of-service code is used: POS 11 (office) or POS 22 (outpatient hospital) are the most common settings.
When patients self-administer Enbrel via prefilled syringe or autoinjector at home, the claim routes to Part D through the patient’s prescription drug plan. The physician office cannot bill J1438 in that scenario. Misrouting a Part D drug onto a Part B claim is a recoverable audit finding that triggers repayment demands. Sound medical billing compliance checks at the point of care catch this before the claim is submitted.
Fee schedule and reimbursement rates
Medicare reimburses HCPCS code J1438 using the Average Sales Price (ASP) methodology. The payment formula is ASP plus 6 percent, and that 6 percent margin is intended to cover acquisition and handling costs for the administering provider.
CMS publishes updated ASP files quarterly, so the reimbursable amount changes four times per year. The CMS Physician Fee Schedule lookup tool allows providers to check the current payment limit before billing.
ASP data reflects average manufacturer prices across all purchasers. Providers who acquire Enbrel above ASP can end up with a negative margin on the drug itself. This is a known risk in the buy-and-bill model for high-cost biologics. Model your acquisition cost against the current ASP rate before committing to an in-office administration program.
Never use a rate from a prior quarter without checking for updates. Submitting claims based on an outdated ASP file is a common audit finding. The CMS HCPCS overview page links directly to the quarterly ASP download files.
How to calculate billing units for HCPCS code J1438
One unit of HCPCS code J1438 covers 25 mg of etanercept. The unit count drives both the number of units billed and the total reimbursement. It is one of the most consequential fields on the claim. Billing the wrong number of units is the most frequently cited error for J-code biologics in audits.
Unit sizes differ from one J-code to the next, so read the descriptor before you count units on any drug line, including J0970 and J2941. Reading it wrong is what turns a clean claim into a repayment demand.
If a portion of the drug is drawn and then discarded, the wasted portion still affects the unit count. Report it with a JW modifier on a separate line. A 50 mg vial used for a 25 mg dose is the usual example. Do not bill for discarded drug without the modifier, and record the administered dose and the discarded volume in the clinical note.
Practices using prescription management software that logs administered drug quantities can pull this data straight into charge capture.
NDC to J-code crosswalk for Enbrel
Medicare and many commercial payers require the National Drug Code (NDC) on the claim alongside HCPCS code J1438. The NDC identifies the specific manufacturer lot, formulation, and package size. It must reflect the product actually administered, never a generic entry.
NDC numbers are 11 digits in the 5-4-2 format as reported on the claim form. Verify current NDCs directly with your drug wholesaler or the Enbrel prescribing information, since lot-level NDCs change with each manufacturing batch.
On a CMS-1500 claim, the NDC qualifier goes in loop 2410 of the electronic file or in the shaded area of box 24 on paper. Report the NDC in units of “ML” for liquid formulations and “UN” for unit-dose products. A missing NDC breaks the clean claim requirement at many payers and causes rejection before adjudication.
Integrated EHR integration for billing workflows can auto-populate the NDC from the dispensed drug record, cutting manual entry errors.
Modifiers that apply to J1438
Several modifiers interact with HCPCS code J1438 depending on the clinical scenario. Using the wrong modifier, or omitting a required one, is a recoverable audit finding. Recovery Audit Contractors (RACs), Unified Program Integrity Contractors (UPICs), and Medicare Administrative Contractors all review these Part B lines.
The JW/JZ modifier pair became mandatory for single-use vials in 2023 under updated CMS policy. Claims for single-use vial drugs submitted without one of these two modifiers are subject to rejection. Billers should hold a standing rule: Every J1438 line carries either JW for wastage or JZ for none. The AAPC HCPCS code lookup includes modifier applicability guidance for each J-code.
Prior authorization requirements
Medicare fee-for-service does not typically require prior authorization for HCPCS code J1438, though some Medicare Advantage plans do. Commercial payers almost universally require prior authorization for Enbrel before the first dose, and often again at each benefit year renewal. The prior authorization process varies by payer and plan, but most follow a similar documentation checklist.
- Confirmed diagnosis: Chart documentation of the qualifying condition, with supporting labs, imaging, or clinical findings. Examples include an anti-CCP antibody result for RA or a PASI score for psoriasis.
- Step therapy evidence: Documented trial and inadequate response to conventional DMARDs, including methotrexate, sulfasalazine, or hydroxychloroquine. Some plans require two prior DMARD failures.
- Prescriber attestation: A signed statement from the ordering physician confirming the clinical rationale.
- NDC or J-code specification: The authorization must name the specific drug. An approval for one TNF inhibitor does not automatically transfer to Enbrel.
Authorization expiration is a silent claim killer. If the authorization lapsed and nobody renewed it before the injection date, the claim denies even though the drug was medically necessary. Build a renewal reminder into the scheduling workflow, or let prior authorization software track expiration dates for you. Recording authorization numbers alongside structured medical documentation also makes an audit response faster.
Pro Tip
Track prior authorization expiration dates for every biologic patient in a shared team calendar or within your EHR. Set a reminder 30 days before expiration to start the renewal. A lapsed authorization on an Enbrel claim usually means a full denial. There is no timely-filing remedy if the renewal lands after the date of service.
Buy-and-bill vs specialty pharmacy for Enbrel
Practices that administer etanercept in-office operate under the buy-and-bill model. The physician office purchases the drug from a wholesaler, administers it on the date of service, and bills HCPCS code J1438 to the payer. This is the only pathway that supports a Part B drug claim.
The alternative is the specialty pharmacy pathway, where the drug is dispensed to the patient for self-administration. Under that model, no J1438 claim is generated at the provider level.
Buy-and-bill demands close inventory tracking and HIPAA-compliant records of every administration. Enbrel also has cold-chain storage requirements, and must be refrigerated between 36 and 46 degrees Fahrenheit. Practices running a regular infusion or injection clinic often handle both jobs inside IV therapy EMR software rather than a separate stock spreadsheet.
Etanercept biosimilars and alternative J-codes
Several FDA-approved biosimilars to Enbrel are commercially available. Biosimilars are not automatically interchangeable with the reference product unless the FDA has granted an interchangeability designation. As of the current CMS HCPCS file, each biosimilar carries its own distinct J-code. Billing J1438 when a biosimilar was actually administered is a claim accuracy violation.
Biosimilar J-codes for etanercept change as CMS updates the HCPCS file. Always confirm the current code in the official CMS HCPCS download before billing a biosimilar formulation. A practice that switches patients between Enbrel and a biosimilar should also update its charge description master, so each product bills under the right code.
Common billing errors and how to avoid them
High-cost biologics generate more preventable denials than any other line in rheumatology and dermatology billing. Below are the six most common errors on J1438 claims, drawn from patterns reported across AAPC coding forums and Medicare audit findings.
- Wrong unit count: Billing 1 unit for a 50 mg dose. One unit of J1438 equals 25 mg, so a 50 mg dose requires 2 units. Check the administered dose in the clinical note before entering units.
- Missing JW or JZ modifier: Every J1438 line involving a single-use vial must carry either JW for discarded drug or JZ for zero waste. Submitting without one results in rejection under CMS post-2023 policy.
- Billing when the patient self-administers: If the patient took the drug home and injected it themselves, J1438 cannot be billed. Confirm the administration route and location in the visit note first.
- Missing NDC on the claim: Most payers reject drug claims without a valid NDC. The NDC must match the lot actually dispensed. Generic entries such as “00000-0000-00” are not acceptable.
- Incorrect place of service: POS 11 belongs to an office visit and POS 22 to a hospital outpatient infusion. Swapping them affects the reimbursement calculation and may trigger edits.
- Billing a biosimilar with J1438: Each FDA-approved biosimilar etanercept has its own HCPCS code. Using J1438 for Erelzi or Eticovo is a claim accuracy error regardless of clinical equivalence.
A pre-claim checklist for biologic J-codes cuts denial rates before submission. Systems that link the dispensed drug record to the claim line remove several of these manual entry points. Where denials still land, a structured denial management process gets the appeal filed inside the payer’s window.
Pro Tip
Run a monthly claim audit on all HCPCS code J1438 lines submitted in the prior 60 days. Check that the units match the documented dose and that JW or JZ is present. Then confirm the NDC appears in the field 24 shaded area. Last, check the diagnosis sits within the FDA-approved ICD-10 categories. Catching these before a RAC audit saves repayment demands and compliance exposure.
How Pabau keeps J1438 documentation and billing in step
In a lot of practices, the record of an in-office Enbrel dose lives in three places. The clinical note lives in the EMR, and the drug and dose sit in a paper log or spreadsheet. The biller then re-types the units and the NDC into the claim. Every hand-off is a chance for the units to drift from the dose.
Practice management software like Pabau keeps all of it in one client record. The prescription and administration details are recorded against the visit, so the documented dose, the product, and the billed units share one source. Claims then go out electronically through our Claim.MD integration, and the remittance comes back into the same system.
For a rheumatology or dermatology practice, that means fewer denials to rework and less time spent proving what was given. When a RAC or UPIC asks for records on a J1438 line, everything is already attached to the visit. The dose, the modifier, and the authorization number sit with the note.
Keep biologic billing tied to the visit note
Pabau records the drug, dose, and authorization against the patient’s visit, then submits the claim electronically. Your rheumatology or dermatology practice bills J1438 straight from what was documented at the point of care.
Conclusion
J1438 rewards practices that treat the claim as part of the clinical encounter. The unit math, the JW or JZ attestation, and the authorization date are all settled at the chair, before the biller opens the claim.
The trade-off worth remembering is margin. ASP plus 6 percent can leave a thin or negative return if your acquisition price sits above the national average. Run those numbers every quarter, then decide deliberately whether in-office administration or the specialty pharmacy route serves the patient better.
Practices that connect documentation to billing catch these errors before submission. Pabau’s claims management software keeps the administration record and the J-code claim in one place. Book a demo to see how it handles biologic charge capture for a rheumatology or dermatology practice.
Continue your research
Billing another physician-administered injectable? HCPCS code J2800 sets out the descriptor, unit math, and coverage rules for that drug code.
Need the unit rules for a different J-code? HCPCS code J3090 covers how to count units and document administration on that claim.
Billing the monitoring visits around a biologic? HCPCS code S0316 sets out how that follow-up code is billed and documented.
Preparing for a documentation audit? HIPAA compliance checklist outlines the documentation and process controls that support billing audit readiness.
Coding for another specialty? IVF CPT codes covers the procedure coding and billing requirements for fertility treatment cycles.
Frequently asked questions
What is HCPCS code J1438 used for?
HCPCS code J1438 bills an injection of etanercept (Enbrel), 25 mg, given under direct physician supervision. When the patient self-administers at home, the drug is dispensed and billed through Medicare Part D instead.
How many units of J1438 are needed for a 50 mg dose?
Two units. Each unit of HCPCS code J1438 covers 25 mg of etanercept. The standard adult dose for rheumatoid arthritis, ankylosing spondylitis, and plaque psoriasis is 50 mg, which equals 2 units on the claim. Billing 1 unit for a 50 mg administration is one of the most common billing errors for this code.
Is J1438 covered under Medicare Part B or Part D?
Part B covers J1438 when etanercept is administered in a physician office or infusion center under direct physician supervision. Part D applies when the patient picks up the drug from a specialty pharmacy and self-administers at home. The two pathways are mutually exclusive for each administration event.
Does J1438 require prior authorization?
Most commercial payers and many Medicare Advantage plans require prior authorization before HCPCS code J1438 can be billed. Traditional Medicare fee-for-service generally does not require prior authorization for J1438, though Local Coverage Determinations from individual MACs may apply. Always verify with the specific payer before the date of service.
What modifiers are required with J1438?
Every J1438 claim line for a single-use vial must carry one of two modifiers. JW reports discarded drug, and JZ attests that the full vial was administered with no waste. This requirement became mandatory under CMS policy updated in 2023. Claims for single-use vial drugs without one of these modifiers are subject to rejection.
What is the Medicare reimbursement rate for J1438?
Medicare reimburses HCPCS code J1438 at ASP plus 6 percent, where ASP is the Average Sales Price reported by the manufacturer. The dollar amount changes each quarter when CMS publishes updated ASP files. Current rates must be verified directly from the CMS quarterly ASP drug pricing file before billing.
